Search

Your search keyword '"Cummings, Christopher"' showing total 479 results
Start Over Author "Cummings, Christopher"

Refine your results

more »

more »

more »

more »

more »
479 results on '"Cummings, Christopher"'

51. Supplementary Figure 4 from UNC569, a Novel Small-Molecule Mer Inhibitor with Efficacy against Acute Lymphoblastic Leukemia In Vitro and In Vivo

Author

Christoph, Sandra, primary, DeRyckere, Deborah, primary, Schlegel, Jennifer, primary, Frazer, J. Kimble, primary, Batchelor, Lance A., primary, Trakhimets, Alesia Y., primary, Sather, Susan, primary, Hunter, Debra M., primary, Cummings, Christopher T., primary, Liu, Jing, primary, Yang, Chao, primary, Kireev, Dmitri, primary, Simpson, Catherine, primary, Norris-Drouin, Jacqueline, primary, Hull-Ryde, Emily A., primary, Janzen, William P., primary, Johnson, Gary L., primary, Wang, Xiaodong, primary, Frye, Stephen V., primary, Earp, H. Shelton, primary, and Graham, Douglas K., primary

Published
2023
Full Text
View/download PDF

52. Supplementary Figure 1 from UNC569, a Novel Small-Molecule Mer Inhibitor with Efficacy against Acute Lymphoblastic Leukemia In Vitro and In Vivo

Author

Christoph, Sandra, primary, DeRyckere, Deborah, primary, Schlegel, Jennifer, primary, Frazer, J. Kimble, primary, Batchelor, Lance A., primary, Trakhimets, Alesia Y., primary, Sather, Susan, primary, Hunter, Debra M., primary, Cummings, Christopher T., primary, Liu, Jing, primary, Yang, Chao, primary, Kireev, Dmitri, primary, Simpson, Catherine, primary, Norris-Drouin, Jacqueline, primary, Hull-Ryde, Emily A., primary, Janzen, William P., primary, Johnson, Gary L., primary, Wang, Xiaodong, primary, Frye, Stephen V., primary, Earp, H. Shelton, primary, and Graham, Douglas K., primary

Published
2023
Full Text
View/download PDF

54. Figure S4 from MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents

Author

McDaniel, Nellie K., primary, Cummings, Christopher T., primary, Iida, Mari, primary, Hülse, Justus, primary, Pearson, Hannah E., primary, Vasileiadi, Eleana, primary, Parker, Rebecca E., primary, Orbuch, Rachel A., primary, Ondracek, Olivia J., primary, Welke, Noah B., primary, Kang, Grace H., primary, Davies, Kurtis D., primary, Wang, Xiaodong, primary, Frye, Stephen V., primary, Earp, H. Shelton, primary, Harari, Paul M., primary, Kimple, Randall J., primary, DeRyckere, Deborah, primary, Graham, Douglas K., primary, and Wheeler, Deric L., primary

Published
2023
Full Text
View/download PDF

55. Data from UNC569, a Novel Small-Molecule Mer Inhibitor with Efficacy against Acute Lymphoblastic Leukemia In Vitro and In Vivo

Author

Christoph, Sandra, primary, DeRyckere, Deborah, primary, Schlegel, Jennifer, primary, Frazer, J. Kimble, primary, Batchelor, Lance A., primary, Trakhimets, Alesia Y., primary, Sather, Susan, primary, Hunter, Debra M., primary, Cummings, Christopher T., primary, Liu, Jing, primary, Yang, Chao, primary, Kireev, Dmitri, primary, Simpson, Catherine, primary, Norris-Drouin, Jacqueline, primary, Hull-Ryde, Emily A., primary, Janzen, William P., primary, Johnson, Gary L., primary, Wang, Xiaodong, primary, Frye, Stephen V., primary, Earp, H. Shelton, primary, and Graham, Douglas K., primary

Published
2023
Full Text
View/download PDF

58. Supplementary Figure 5 from UNC569, a Novel Small-Molecule Mer Inhibitor with Efficacy against Acute Lymphoblastic Leukemia In Vitro and In Vivo

Author

Christoph, Sandra, primary, DeRyckere, Deborah, primary, Schlegel, Jennifer, primary, Frazer, J. Kimble, primary, Batchelor, Lance A., primary, Trakhimets, Alesia Y., primary, Sather, Susan, primary, Hunter, Debra M., primary, Cummings, Christopher T., primary, Liu, Jing, primary, Yang, Chao, primary, Kireev, Dmitri, primary, Simpson, Catherine, primary, Norris-Drouin, Jacqueline, primary, Hull-Ryde, Emily A., primary, Janzen, William P., primary, Johnson, Gary L., primary, Wang, Xiaodong, primary, Frye, Stephen V., primary, Earp, H. Shelton, primary, and Graham, Douglas K., primary

Published
2023
Full Text
View/download PDF

60. Table S1 from MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents

Author

McDaniel, Nellie K., primary, Cummings, Christopher T., primary, Iida, Mari, primary, Hülse, Justus, primary, Pearson, Hannah E., primary, Vasileiadi, Eleana, primary, Parker, Rebecca E., primary, Orbuch, Rachel A., primary, Ondracek, Olivia J., primary, Welke, Noah B., primary, Kang, Grace H., primary, Davies, Kurtis D., primary, Wang, Xiaodong, primary, Frye, Stephen V., primary, Earp, H. Shelton, primary, Harari, Paul M., primary, Kimple, Randall J., primary, DeRyckere, Deborah, primary, Graham, Douglas K., primary, and Wheeler, Deric L., primary

Published
2023
Full Text
View/download PDF

62. Supplementary Data S1, S2 from Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors

Author

Kazi, Aslamuzzaman, primary, Xiang, Shengyan, primary, Yang, Hua, primary, Chen, Liwei, primary, Kennedy, Perry, primary, Ayaz, Muhammad, primary, Fletcher, Steven, primary, Cummings, Christopher, primary, Lawrence, Harshani R., primary, Beato, Francisca, primary, Kang, Ya'an, primary, Kim, Michael P., primary, Delitto, Andrea, primary, Underwood, Patrick W., primary, Fleming, Jason B., primary, Trevino, Jose G., primary, Hamilton, Andrew D., primary, and Sebti, Said M., primary

Published
2023
Full Text
View/download PDF

63. Data from Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors

Author

Kazi, Aslamuzzaman, primary, Xiang, Shengyan, primary, Yang, Hua, primary, Chen, Liwei, primary, Kennedy, Perry, primary, Ayaz, Muhammad, primary, Fletcher, Steven, primary, Cummings, Christopher, primary, Lawrence, Harshani R., primary, Beato, Francisca, primary, Kang, Ya'an, primary, Kim, Michael P., primary, Delitto, Andrea, primary, Underwood, Patrick W., primary, Fleming, Jason B., primary, Trevino, Jose G., primary, Hamilton, Andrew D., primary, and Sebti, Said M., primary

Published
2023
Full Text
View/download PDF

65. Peptide ligands for the affinity purification of adeno-associated viruses from HEK 293 cell lysates

Author

Menegatti, Stefano, primary, Chu, Wenning, additional, Shastry, Shriarjun, additional, Barbieri, Eduardo, additional, Prodromou, Raphael, additional, Greback-Clarke, Paul, additional, Smith, Will, additional, Moore, Brandyn, additional, Kilgore, Ryan, additional, Cummings, Christopher, additional, Pancorbo, Jennifer, additional, Gilleskie, Gary, additional, and Daniele, Michael A., additional

Published
2023
Full Text
View/download PDF

66. Peptide ligands for the affinity purification of adeno-associated viruses from HEK 293 cell lysates

Author

Chu, Wenning, primary, Shastry, Shriarjun, additional, Barbieri, Eduardo, additional, Prodromou, Raphael, additional, Greback-Clarke, Paul, additional, Smith, Will, additional, Moore, Brandyn, additional, Kilgore, Ryan, additional, Cummings, Christopher, additional, Pancorbo, Jennifer, additional, Gilleskie, Gary, additional, Daniele, Michael A., additional, and Menegatti, Stefano, additional

Published
2023
Full Text
View/download PDF

67. Peptide ligands for the affinity purification of adeno‐associated viruses from HEK 293 cell lysates.

Author

Chu, Wenning, Shastry, Shriarjun, Barbieri, Eduardo, Prodromou, Raphael, Greback‐Clarke, Paul, Smith, Will, Moore, Brandyn, Kilgore, Ryan, Cummings, Christopher, Pancorbo, Jennifer, Gilleskie, Gary, Daniele, Michael A., and Menegatti, Stefano

Abstract

Adeno‐associated viruses (AAVs) are the vector of choice for delivering gene therapies that can cure inherited and acquired diseases. Clinical research on various AAV serotypes significantly increased in recent years alongside regulatory approvals of AAV‐based therapies. The current AAV purification platform hinges on the capture step, for which several affinity resins are commercially available. These adsorbents rely on protein ligands—typically camelid antibodies—that provide high binding capacity and selectivity, but suffer from low biochemical stability and high cost, and impose harsh elution conditions (pH < 3) that can harm the transduction activity of recovered AAVs. Addressing these challenges, this study introduces peptide ligands that selectively capture AAVs and release them under mild conditions (pH = 6.0). The peptide sequences were identified by screening a focused library and modeled in silico against AAV serotypes 2 and 9 (AAV2 and AAV9) to select candidate ligands that target homologous sites at the interface of the VP1‐VP2 and VP2‐VP3 virion proteins with mild binding strength (KD ~ 10−5–10−6 M). Selected peptides were conjugated to Toyopearl resin and evaluated via binding studies against AAV2 and AAV9, demonstrating the ability to target both serotypes with values of dynamic binding capacity (DBC10% > 1013 vp/mL of resin) and product yields (~50%–80%) on par with commercial adsorbents. The peptide‐based adsorbents were finally utilized to purify AAV2 from a HEK 293 cell lysate, affording high recovery (50%–80%), 80‐ to 400‐fold reduction of host cell proteins (HCPs), and high transduction activity (up to 80%) of the purified viruses. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

74. Gene‐Edited Food Adoption Intentions and Institutional Trust in the United States: Benefits, Acceptance, and Labeling☆.

Author

Lindberg, Sonja A., Peters, David J., and Cummings, Christopher L.

Subjects
TRUST, PLANNED behavior theory, CONSUMER activism, GENETICALLY modified foods, GREEN movement, PUBLIC opinion
Abstract

New gene editing techniques, such as CRISPR‐Cas9, have created the potential for rapid development of new gene‐edited food (GEF) products. Unlike genetically modified organism foods, there is limited research and literature on U.S. public opinions about GEFs. We address this knowledge gap by examining how crop‐based GEF adoption is linked to public trust in institutions and values using the Theory of Planned Behavior. We employ ordinal regression models to predict adoption intentions (direct benefits, acceptability, willingness to eat, and labeling) using a unique and nationally representative survey of n = 2,000 adults in the United States. We find that adoption hinges on public trust in institutions overseeing GEF development, especially trust in university scientists. The 29 percent of Americans likely to adopt GEFs highly trust government food regulators and the biotech industry. A nearly equal number of likely non‐adopters distrust current regulatory systems in favor of consumer and environmental advocacy groups. However, most Americans (41 percent) are uncertain about GEF adoption and whom to trust. Although 75 percent of Americans want GEFs labeled, few trust government agencies who have authority to issue labels. Our findings suggest public trust in GEFs and labels can only be obtained by tripartite oversight by universities, advocacy groups, and government food regulators. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

80. UNC1062, a new and potent Mer inhibitor

Author

Liu, Jing, Zhang, Weihe, Stashko, Michael A., DeRyckere, Deborah, Cummings, Christopher T., Hunter, Debra, Yang, Chao, Jayakody, Chatura N., Cheng, Nancy, Simpson, Catherine, Norris-Drouin, Jacqueline, Sather, Susan, Kireev, Dmitri, Janzen, William P., Earp, H. Shelton, Graham, Douglas K., Frye, Stephen V., and Wang, Xiaodong

Published
2013
Full Text
View/download PDF

82. Biallelic GTF2IRD1 variants in brothers with profound neurodevelopmental disorder: A possible novel disorder involving a critical gene for Williams syndrome.

Author

Cummings, Christopher Thomas and Starr, Lois Janelle

Abstract

GTF2IRD1, a gene on chromosome 7 which encodes a transcription factor, is of significant clinical interest due to its heterozygous loss as part of the classical deletion associated with Williams–Beuren syndrome (WBS). However, biallelic variants in GTF2IRD1 alone as part of an autosomal recessive disease have not been previously reported. Here, we present two full brothers with variants in trans of GTF2IRD1 at c.1231C > T (p.Arg411Trp) and c.2632C > G (p.Leu878Val). A detailed clinical phenotype is described, which includes severe neurodevelopmental disability, facial dysmorphology, and pectus excavatum. Importantly, out of eight full siblings, only these two brothers harboring both variants in trans present with the profound described phenotype. We present the possibility that these brothers represent the identification of a new syndrome characterized by biallelic variants in GTF2IRD1, which may also have important implications for the molecular etiology of WBS. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

97. Can Comorbidity Data Explain Cross-State and Cross-National Difference in COVID-19 Death Rates?

Author

Cegan, Jeffrey C, primary, Trump, Benjamin D, additional, Cibulsky, Susan M, additional, Collier, Zachary A, additional, Cummings, Christopher L, additional, Greer, Scott L, additional, Jarman, Holly, additional, Klasa, Kasia, additional, Kleinman, Gary, additional, Surette, Melissa A, additional, Wells, Emily, additional, and Linkov, Igor, additional

Published
2021
Full Text
View/download PDF

100. Can Comorbidity Data Explain Cross-State and Cross-National Difference in COVID-19 Death Rates?

Author

Cegan,Jeffrey C, Trump,Benjamin D, Cibulsky,Susan M, Collier,Zachary A, Cummings,Christopher L, Greer,Scott L, Jarman,Holly, Klasa,Kasia, Kleinman,Gary, Surette,Melissa A, Wells,Emily, Linkov,Igor, Cegan,Jeffrey C, Trump,Benjamin D, Cibulsky,Susan M, Collier,Zachary A, Cummings,Christopher L, Greer,Scott L, Jarman,Holly, Klasa,Kasia, Kleinman,Gary, Surette,Melissa A, Wells,Emily, and Linkov,Igor

Abstract

Jeffrey C Cegan,1 Benjamin D Trump,1 Susan M Cibulsky,2 Zachary A Collier,3 Christopher L Cummings,4 Scott L Greer,5 Holly Jarman,5 Kasia Klasa,1,5 Gary Kleinman,2 Melissa A Surette,6 Emily Wells,1 Igor Linkov1 1US Army Engineer Research and Development Center, US Army Corps of Engineers, Vicksburg, MS, USA; 2US Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Boston, MA, USA; 3Radford University, Davis College of Business and Economics, Department of Management, Radford, VA, USA; 4North Carolina State University, Genetic Engineering and Society Center, Raleigh, NC, USA; 5University of Michigan, School of Public Health, Department of Health Management and Policy, Ann Arbor, MI, USA; 6Federal Emergency Management Agency, Region I, Boston, MA, USACorrespondence: Jeffrey C Cegan; Igor LinkovUS Army Engineer Research and Development Center, US Army Corps of Engineers, 696 Virginia Road, Concord, MA, 01742, USATel +1-978-318-8881; +1-617-233-9869Email Jeffrey.C.Cegan@usace.army.mil; Igor.Linkov@usace.army.milAbstract: Many efforts to predict the impact of COVID-19 on hospitalization, intensive care unit (ICU) utilization, and mortality rely on age and comorbidities. These predictions are foundational to learning, policymaking, and planning for the pandemic, and therefore understanding the relationship between age, comorbidities, and health outcomes is critical to assessing and managing public health risks. From a US government database of 1.4 million patient records collected in May 2020, we extracted the relationships between age and number of comorbidities at the individual level to predict the likelihood of hospitalization, admission to intensive care, and death. We then applied the relationships to each US state and a selection of different countries in order to see whether they predicted observed outcome rates. We found that age and comorbidity data within these geographical regions do not explain much of the

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results